NO176549C - Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk - Google Patents

Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk

Info

Publication number
NO176549C
NO176549C NO873589A NO873589A NO176549C NO 176549 C NO176549 C NO 176549C NO 873589 A NO873589 A NO 873589A NO 873589 A NO873589 A NO 873589A NO 176549 C NO176549 C NO 176549C
Authority
NO
Norway
Prior art keywords
dopa
cores
coatings
preparing
weight during
Prior art date
Application number
NO873589A
Other languages
English (en)
Other versions
NO873589D0 (no
NO176549B (no
NO873589L (no
Inventor
Curt Henry Appelgren
Eva Christina Eskilsson
Original Assignee
Asta Pharma Ag
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag, Lejus Medical Ab filed Critical Asta Pharma Ag
Publication of NO873589D0 publication Critical patent/NO873589D0/no
Publication of NO873589L publication Critical patent/NO873589L/no
Publication of NO176549B publication Critical patent/NO176549B/no
Publication of NO176549C publication Critical patent/NO176549C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
NO873589A 1986-08-26 1987-08-25 Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk NO176549C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (4)

Publication Number Publication Date
NO873589D0 NO873589D0 (no) 1987-08-25
NO873589L NO873589L (no) 1988-02-29
NO176549B NO176549B (no) 1995-01-16
NO176549C true NO176549C (no) 1995-04-26

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO873589A NO176549C (no) 1986-08-26 1987-08-25 Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk

Country Status (15)

Country Link
US (1) US4981695A (no)
EP (1) EP0260236B1 (no)
JP (1) JPH0662405B2 (no)
AT (1) ATE58292T1 (no)
CA (1) CA1298198C (no)
DD (1) DD286107A5 (no)
DE (1) DE3766200D1 (no)
DK (1) DK442287A (no)
ES (1) ES2036221T3 (no)
FI (1) FI86689C (no)
HU (1) HU197211B (no)
MX (1) MX172918B (no)
NO (1) NO176549C (no)
PT (1) PT85591B (no)
SE (1) SE460947B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
BR0211358A (pt) * 2001-07-26 2004-09-21 Merck Patent Gmbh Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
WO2005041925A2 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20090227673A1 (en) * 2006-01-13 2009-09-10 Bao Ting Zhu Method and Composition for the Treatment of Parkinson's Disease
WO2007103286A2 (en) * 2006-03-02 2007-09-13 Spherics, Inc. Rate-controlled bioadhesive oral dosage formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (no) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
HU197211B (en) 1989-03-28
PT85591B (pt) 1990-05-31
DE3766200D1 (de) 1990-12-20
ATE58292T1 (de) 1990-11-15
ES2036221T3 (es) 1993-05-16
JPS63139128A (ja) 1988-06-10
EP0260236A1 (en) 1988-03-16
DK442287A (da) 1988-02-27
FI873672A0 (fi) 1987-08-25
HUT44438A (en) 1988-03-28
DD286107A5 (de) 1991-01-17
NO873589D0 (no) 1987-08-25
US4981695A (en) 1991-01-01
PT85591A (en) 1987-09-01
EP0260236B1 (en) 1990-11-14
NO176549B (no) 1995-01-16
FI86689B (fi) 1992-06-30
FI86689C (fi) 1992-10-12
NO873589L (no) 1988-02-29
CA1298198C (en) 1992-03-31
DK442287D0 (da) 1987-08-25
JPH0662405B2 (ja) 1994-08-17
SE8603582D0 (sv) 1986-08-26
SE460947B (sv) 1989-12-11
FI873672L (fi) 1988-02-27
SE8603582L (sv) 1988-02-27
MX172918B (es) 1994-01-21

Similar Documents

Publication Publication Date Title
HUT44438A (en) Composition comprising l-dopa
EP0500143A3 (en) Pharmaceutical composition comprising an aminoglycoside phosphate
NO943093L (no) Fremgangsmåte for fremstilling av clavulansyre
ATE53038T1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
HUT60740A (en) Process for producing new thiophnecarboxylic acid esters of amino-alcohols, their quaternary derivatives and pharmaceutical compositions comprising same as active ingredient
HUT52070A (en) Herbicide compositions containing pyrimidinyl-benzoic acid derivatives as active components, and process for producing the active components
IE851918L (en) An indole derivative.
DE58900183D1 (de) Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
SE8703169D0 (sv) 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h-2,3-benzodiazepine, acid addition salts thereof and process for preparing same
EP0293751A3 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
GEP19971030B (en) Method for preparation of derivatives of 1-benzil-3-oximetil-indazolului or salts with pharmaceutically acceptable bases
HU901428D0 (en) Process for the preparation of 5-substituted 1,4-dihydro-4-oxo-naphthiridine-3-carboxylic acid derivatives
ATA379182A (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
AU621191B2 (en) Aminalkoxyphenyl derivatives, process for their preparation and compositions containing them
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
SE8803583L (sv) Farmaceutisk komposition
EP0177087A3 (en) 1h-indol-3-yl containing 1,3-dimethyl-1h-purine-2,6-diones
DE3764235D1 (de) Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
AU1413788A (en) Dihydropyridinamides process for their preparation, and their use in medicaments
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
HUT47375A (en) Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components
HUT56353A (en) Herbicidal compositions comprising salicilic acid derivatives and process for producing the active ingredients
AU588414B2 (en) Methionine-substituted 1, 4-dihydropyridines, process for the preparation and their use
IT8322238A0 (it) Sali di endo-8,8-dialchil-8-azoniabiciclo [3.2.1.] ottan-6,7-eso-epossi-3-alchilcarbossilati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo